Online inquiry

IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ208MR)

This product GTTS-WQ208MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ208MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3978MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ6584MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ3340MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ7044MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ8854MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ10126MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ1292MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ6956MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW